Thermo Fisher Scientific's Trading Volume Drops 30% Despite $689 Million in Shares Traded

On June 24, 2025, Thermo Fisher Scientific (TMO) experienced a significant drop in trading volume, with a total of $689 million in shares traded, marking a 30.34% decrease from the previous day. Despite this decline, TMO's stock price has been on an upward trajectory, rising by 1.00% over the past four days, accumulating a total increase of 3.57%.

Thermo Fisher Scientific has recently secured a substantial $94.5 million contract from the U.S. government. This contract involves supplying the Navy with advanced radiation detection systems, including the Navy Occupational Dosimetry System (NODS) devices and the Navy Radiation Exposure Management System (NAVREMS). This award highlights the company's expertise in delivering cutting-edge dosimetry technology and data management solutions, further solidifying its position as a trusted provider in the defense sector.

In addition to its defense contracts, Thermo Fisher Scientific has been actively engaged in various research collaborations. The company has partnered with Xcell Biosciences to advance the next generation of cell therapies. This collaboration aims to leverage Thermo Fisher's technology platforms to develop innovative therapeutic solutions. Furthermore, Thermo Fisher has also collaborated with Ethris to provide access to mRNA technology platforms, enhancing its capabilities in the biotechnology sector.

Thermo Fisher Scientific continues to innovate in the field of mass spectrometry. The company recently unveiled its next-generation mass spectrometers at the ASMS 2025 conference. These advanced instruments are designed to revolutionize biopharma applications and omics research, further cementing Thermo Fisher's leadership in scientific instrumentation.